Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 12 years
- Director since
- 2023
12 years of board service in total across 4 boards, counting each seat separately. Longest: Syndax Pharmaceuticals Inc., 3 years.
Syndax Pharmaceuticals Inc.
Director · President, Head of R&D
Arvinas Inc.
Director
Werewolf Therapeutics Inc.
Director
CRISPR Therapeutics AG
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
CRISPR Therapeutics AG June 4, 202693.2%
-
Werewolf Therapeutics Inc. June 12, 202575.2%
-
CRISPR Therapeutics AG June 5, 202597.0%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 24, 2026 | Arvinas Inc. | Grant or award | +15,527 | — | — |
| Mar 6, 2026 | Arvinas Inc. | Open-market purchase | +20,000 | $13.40 | $268,000 |
| Sep 22, 2025 | Arvinas Inc. | Open-market purchase | +30,000 | $7.57 | $227,100 |
| Jun 25, 2025 | Arvinas Inc. | Grant or award | +16,025 | — | — |
| May 29, 2024 | Arvinas Inc. | Grant or award | +5,899 | — | — |
| Feb 7, 2024 | Syndax Pharmaceuticals Inc. | Grant or award | +17,000 | — | — |
| Aug 9, 2023 | Syndax Pharmaceuticals Inc. | Option exercise | +52,855 | $8.77 | $463,538 |
| Aug 9, 2023 | Syndax Pharmaceuticals Inc. | Open-market sale | −52,855 | $18.27 | $965,661 |
| Jul 10, 2023 | Syndax Pharmaceuticals Inc. | Option exercise | +52,855 | $8.77 | $463,538 |
| Jul 10, 2023 | Syndax Pharmaceuticals Inc. | Open-market sale | −52,855 | $20.40 | $1,078,242 |
| Jun 15, 2023 | Arvinas Inc. | Grant or award | +4,121 | — | — |
| Jun 9, 2023 | Syndax Pharmaceuticals Inc. | Option exercise | +24,582 | $6.38 | $156,833 |
| Jun 9, 2023 | Syndax Pharmaceuticals Inc. | Option exercise | +28,273 | $8.77 | $247,954 |
| Jun 9, 2023 | Syndax Pharmaceuticals Inc. | Open-market sale | −24,582 | $21.18 | $520,647 |
| Jun 9, 2023 | Syndax Pharmaceuticals Inc. | Open-market sale | −28,273 | $21.18 | $598,822 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.